大博医疗(002901) - 2022 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2022 was CNY 431,071,714.35, representing a 14.94% increase compared to CNY 375,030,218.30 in the same period last year[6] - Net profit attributable to shareholders decreased by 14.58% to CNY 111,527,418.23 from CNY 130,569,345.57 year-on-year[6] - Total operating revenue for the first quarter was 431,071,714.35, an increase from 375,030,218.30 in the previous year, representing a growth of approximately 15%[22] - Net profit for the first quarter was 114,474,304.94, down from 134,814,713.36, indicating a decrease of approximately 15%[24] - The company achieved a total comprehensive income of 115,115,756.41, down from 135,090,185.91, indicating a decrease of about 15%[27] - Basic earnings per share decreased to 0.27 from 0.33, a decline of approximately 18%[27] Cash Flow and Investments - The net cash flow from operating activities was negative at CNY -110,519,784.68, a decline of 309.62% compared to CNY 52,724,072.25 in the previous year[6] - The company reported a net cash outflow from operating activities of -110,519,784.68, compared to a positive cash inflow of 52,724,072.25 in the previous year[29] - The net cash flow from investment activities was -64,805,198.44 CNY, compared to -77,983,483.96 CNY in the previous period, indicating an improvement[31] - The total cash inflow from financing activities was 488,320,000.00 CNY, while the cash outflow was 2,340,614.57 CNY, resulting in a net cash flow of 485,979,385.43 CNY[31] - The net increase in cash and cash equivalents for the quarter was 310,799,583.82 CNY, contrasting with a decrease of 24,950,777.27 CNY in the previous period[31] - The ending balance of cash and cash equivalents was 372,551,453.52 CNY, up from 23,188,152.58 CNY in the previous period[31] - The cash inflow from investment activities totaled 1,251,735,262.06 CNY, while cash outflow was 1,316,540,460.50 CNY, leading to a net cash flow from investment activities of -64,805,198.44 CNY[31] Assets and Liabilities - Total assets increased by 13.74% to CNY 3,844,343,059.44 from CNY 3,379,858,314.48 at the end of the previous year[6] - Current liabilities decreased to ¥575,274,039.45 from ¥721,780,002.69, a reduction of approximately 20.3%[19] - The total liabilities decreased to 640,299,589.92 from 791,470,911.11, a reduction of approximately 19%[22] - The company's equity attributable to shareholders rose by 24.37% to CNY 3,124,699,338.95 from CNY 2,512,476,209.50[6] - The equity attributable to shareholders increased to 3,124,699,338.95 from 2,512,476,209.50, reflecting a growth of about 24%[22] Shareholder Information - The total number of common shareholders at the end of the reporting period was 26,234[10] - The largest shareholder, Changdu Dabotong Medical Investment Management Co., Ltd., holds 43.13% of the shares, totaling 179,928,000 shares[10] - The top ten shareholders include significant stakes from both domestic and foreign entities, with the largest foreign shareholder holding 22.07%[14] Research and Development - Research and development expenses increased by 51.92% to CNY 47,245,795.19 from CNY 31,098,383.66 year-on-year[8] - Research and development expenses rose to 47,245,795.19 from 31,098,383.66, marking an increase of about 52%[24] Government Support and Market Conditions - The company received government subsidies amounting to CNY 9,091,685.84, a 119.35% increase from CNY 4,144,922.30 in the previous year[9] - The fair value changes of financial assets resulted in a gain of CNY 4,503,165.72, a significant increase of 2039.38% compared to a loss of CNY -232,196.67 in the previous year[9] - The company is facing challenges due to the implementation of bulk purchasing results and the impact of recurring COVID-19 outbreaks on its operational performance[17] - The company is actively exploring new strategies and market expansions in response to competitive pressures in the medical supplies sector[17] Operational Costs - Total operating costs increased to 313,846,809.66 from 222,749,392.94, reflecting a rise of about 41%[22] - Cash received from sales of goods and services was 395,785,137.20, a decrease from 408,213,543.76 in the previous year[29] Audit Information - The company did not conduct an audit for the first quarter report[32]